Frequency Therapeutics, Inc. (FREQ)
After hours:
- Business Wire
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
LEXINGTON, Mass., May 18, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose will present at the upcoming H.C. Wainwright Global Investment Conference.
- Business Wire
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
LEXINGTON, Mass., May 04, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2022.
- Business Wire
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
LEXINGTON, Mass., April 22, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose and Vice President of Discovery Biology Dr. Sanjay Magavi will participate in a fireside presentation at the B. Riley Securities’ Neuro & Ophthalmology Conference on April 28, 2022 at 3:30 pm ET.
